human multiple myeloma cell line u266  (Procell Inc)

Journal: Annals of Hematology

Article Title: MMSA-1 is regulated by Wnt/TCF4 and involved in multiple myeloma progression and invasion via RAS/RAF signaling pathway

doi: 10.1007/s00277-026-06740-8

Figure Lengend Snippet: Identification of constructed TCF4−/+ U266 and MMSA−1−/+ U266 stable cell lines and MMSA-1 mRNA and protein levels in TCF4−/+ U266 cells 1: U266 cells; 2: TCF4− U266-NC; 3. TCF4− U266 cells; 4: TCF4+ U266-NC; 5. TCF4+ U266 cells

Article Snippet: Human multiple myeloma cell line U266 and 293 T were purchased from Wuhan Procell Life Science&Technology Co., Ltd, both of which have been identified by Short Tandem Repeat (STR).

Techniques: Construct, Stable Transfection

Journal: Annals of Hematology

Article Title: MMSA-1 is regulated by Wnt/TCF4 and involved in multiple myeloma progression and invasion via RAS/RAF signaling pathway

doi: 10.1007/s00277-026-06740-8

Figure Lengend Snippet: Dual-Luciferase Report Assay results in different U266 cells

Article Snippet: Human multiple myeloma cell line U266 and 293 T were purchased from Wuhan Procell Life Science&Technology Co., Ltd, both of which have been identified by Short Tandem Repeat (STR).

Techniques: Luciferase

Journal: Annals of Hematology

Article Title: MMSA-1 is regulated by Wnt/TCF4 and involved in multiple myeloma progression and invasion via RAS/RAF signaling pathway

doi: 10.1007/s00277-026-06740-8

Figure Lengend Snippet: MMSA-1 and RAS co-localization and interaction in U266 cells 1: U266 cells; 2: MMSA−1− U266-NC; 3. MMSA−1− U266 cells; 4: MMSA−1+ U266-NC; 5. MMSA−1+ U266 cells

Article Snippet: Human multiple myeloma cell line U266 and 293 T were purchased from Wuhan Procell Life Science&Technology Co., Ltd, both of which have been identified by Short Tandem Repeat (STR).

Techniques:

Journal: Annals of Hematology

Article Title: MMSA-1 is regulated by Wnt/TCF4 and involved in multiple myeloma progression and invasion via RAS/RAF signaling pathway

doi: 10.1007/s00277-026-06740-8

Figure Lengend Snippet: RAS downstream related molecule expressions in different U266 cells 1: U266; 2: MMSA−1− U266-NC; 3. MMSA−1− U266; 4: MMSA−1+ U266-NC; 5. MMSA−1 + U266

Article Snippet: Human multiple myeloma cell line U266 and 293 T were purchased from Wuhan Procell Life Science&Technology Co., Ltd, both of which have been identified by Short Tandem Repeat (STR).

Techniques:

Journal: Annals of Hematology

Article Title: MMSA-1 is regulated by Wnt/TCF4 and involved in multiple myeloma progression and invasion via RAS/RAF signaling pathway

doi: 10.1007/s00277-026-06740-8

Figure Lengend Snippet: MMSA-1’s effect on U266 cells proliferation, migration and apoptosis A showed cloning formation assay result; B showed transwell assay result; C showed apoptosis related proteins expression and D showed mitochondrial apoptosis in different U266 cells. 1: U266; 2: U266 + CCCP-1; 3. MMSA−1− U266-NC; 4. MMSA−1− U266-NC + CCCP-1; 5. MMSA−1− U266; 6: MMSA−1− U266 + CCCP-1; 7. MMSA−1+ U266-NC; 8. MMSA−1+ U266-NC + CCCP-1; 9. MMSA−1 + U266; 10. MMSA−1 + U266 + CCCP-1

Article Snippet: Human multiple myeloma cell line U266 and 293 T were purchased from Wuhan Procell Life Science&Technology Co., Ltd, both of which have been identified by Short Tandem Repeat (STR).

Techniques: Migration, Cloning, Tube Formation Assay, Transwell Assay, Expressing

Journal: Annals of Hematology

Article Title: MMSA-1 is regulated by Wnt/TCF4 and involved in multiple myeloma progression and invasion via RAS/RAF signaling pathway

doi: 10.1007/s00277-026-06740-8

Figure Lengend Snippet: Adhesion molecules and angiogenesis factors levels in different U266 cells A showed qRT-PCR result and B showed Western Blot result of adhesion molecules; C showed angiogenesis factors levels. 1: U266 cells, 2: MMSA−1− U266-NC; 3. MMSA−1− U266; 4. MMSA−1+ U266-NC; 5. MMSA−1+ U266

Article Snippet: Human multiple myeloma cell line U266 and 293 T were purchased from Wuhan Procell Life Science&Technology Co., Ltd, both of which have been identified by Short Tandem Repeat (STR).

Techniques: Quantitative RT-PCR, Western Blot

Journal: Scientific Reports

Article Title: Leukoreduction filter derived NK cells offer a promising source for off the shelf CAR NK cell immunotherapy

doi: 10.1038/s41598-025-97584-1

Figure Lengend Snippet: High cytotoxicity of anti-BCMA CAR LRF-NK and PB-NK cells against BCMA-expressing cells. ( A ) Flow cytometric analysis depicts CD107a expression on anti-BCMA CAR LRF-NK cells (GFP + population) post-co-culture with U266-B1 cells (BCMA + cells). ( B ) the mean percentage of CD107a expression on anti-BCMA CAR LRF-NK cells (GFP + population) after co-culture with CCRF-CEM (BCMA − cells) and K562 cell lines. ( C ) Statistical analysis indicates significantly elevated CD107a expression on anti-BCMA CAR LRF- and PB-NK cells when co-cultured with U266-B1 compared to CCRF-CEM and K562 cells. No significant difference in CD107a expression exists between anti-BCMA CAR LRF- and PB-NK cells. Data presented as Mean ± SD. (** Represents P < 0.001, and *** P < 0.0001, N = 3). LRF: Leukocyte reduction filter. PB: peripheral blood.

Article Snippet: The human BCMA + multiple myeloma cell line (U266-B1), BCMA- acute lymphoblastic leukemia cell line (CCRF-CEM), human erythroleukemic cell line (K562), and human embryonic kidney cell line (HEK293T) were procured from the Pasteur Institute (Tehran, Iran).

Techniques: Expressing, Co-Culture Assay, Cell Culture

Journal: Scientific Reports

Article Title: Leukoreduction filter derived NK cells offer a promising source for off the shelf CAR NK cell immunotherapy

doi: 10.1038/s41598-025-97584-1

Figure Lengend Snippet: Specific activation of transduced NK cells. ( A ) The baseline expression levels of CD69 (upper left) on anti-BCMA CAR LRF-NK cells, when cultured alone and CD69 expression following the co-cultivation of anti-BCMA CAR LRF-NK cells with U266-B1 (upper right) CCRF-CEM (Lower Left) and K562 (lower left) cell lines. ( B ) The mean percentage of CD69 as an early activation marker significantly increased on anti-BCMA CAR LRF/PB cells following co-cultivation with the U266-B1 compared to CCRF-CEM cell lines.

Article Snippet: The human BCMA + multiple myeloma cell line (U266-B1), BCMA- acute lymphoblastic leukemia cell line (CCRF-CEM), human erythroleukemic cell line (K562), and human embryonic kidney cell line (HEK293T) were procured from the Pasteur Institute (Tehran, Iran).

Techniques: Activation Assay, Expressing, Cell Culture, Marker

Journal: Scientific Reports

Article Title: Leukoreduction filter derived NK cells offer a promising source for off the shelf CAR NK cell immunotherapy

doi: 10.1038/s41598-025-97584-1

Figure Lengend Snippet: mRNA expression of IFN-γ ( A ) and granzyme B ( B ) in anti-BCMA CAR LRF-NK and PB-NK cells following co-culture with U266-B1 (BCMA + ), CCRF-CEM (BCMA − ), and K562 Cell Lines. The augmented expression of IFN-γ and granzyme B was evident in LRF-NK and PB-NK cells after co-cultivation with the K562 cell line, as opposed to their counterparts co-cultivated with U266-B1 and CCRF-CEM cell lines, as well as IL-2 treated NK cells. No statistically significant distinctions were discerned between LRF-NK and PB-NK cells. Conversely, Anti-BCMA CAR NK cells demonstrated a notable increase in the expression of IFN-γ and GrB after co-culture with U266-B1 compared to CCRF-CEM. The absence of significant differences between LRF and PB CAR NK cells in IFN-γ and GrB expression under identical conditions is noteworthy. Notably, a significantly heightened expression of IFN-γ and GrB in CAR NK cells compared to regular NK cells was observed after co-culture with U266-B1 cells. Data are presented as mean ± SD. (Double asterisks (**) signify P < 0.001, and triple asterisks (***) denote P < 0.0001; N = 3). LRF: leukocyte reduction filter. PB: peripheral blood.

Article Snippet: The human BCMA + multiple myeloma cell line (U266-B1), BCMA- acute lymphoblastic leukemia cell line (CCRF-CEM), human erythroleukemic cell line (K562), and human embryonic kidney cell line (HEK293T) were procured from the Pasteur Institute (Tehran, Iran).

Techniques: Expressing, Co-Culture Assay

Journal: Cells

Article Title: Pre-Clinical Assessment of SAR442257, a CD38/CD3xCD28 Trispecific T Cell Engager in Treatment of Relapsed/Refractory Multiple Myeloma

doi: 10.3390/cells13100879

Figure Lengend Snippet: Characterization of SAR442257 potency in human multiple myeloma cell lines (HMCLs): ( a ) SAR442257 geometry; ( b ) correlation of target expression (in molecules of equivalent soluble fluorochrome (MESF)) of CD38 and CD28 on 10 HMCL. We measured CD38 and CD28 target expression and found a linear relationship with Pearson’s r = 0.7, p = 0.03. ( c – e ) Cellular avidity ranks as a percentage of TCs bound to MM cells by indicated TC engagers (triple knockout (KO), SAR442257, CD38-CD3-antibody (AB), CD28-CD3-AB, CD38 AB) for U266 ( d ) and MM1S ( e ). ( f – h ) Dose response curves of SAR442257 or triple KO control in ( g ) U266 and ( h ) MM1S with healthy donor TCs (E:T = 10:1). (Significance was determined using TTEST, * p < 0.05, *** p < 0.001).

Article Snippet: Human multiple myeloma cell lines (HMCL), i.e., MM1S, U266, AMO, AMO-TP53, RPMI 8226, INA-6, OPM-2, LP-1, KMS-11BM, and KMS-11, were purchased from DSMZ (Braunschweig, Germany).

Techniques: Expressing, Triple Knockout, Control

Journal: Nutrients

Article Title: Vitamin D and K Supplementation Is Associated with Changes in the Methylation Profile of U266-Multiple Myeloma Cells, Influencing the Proliferative Potential and Resistance to Bortezomib.

doi: 10.3390/nu16010142

Figure Lengend Snippet: Figure 1. Methylation profile after three consecutive BTZ treatments of U266 myeloma cells. (A,B) charts show differences in methylation levels in BTZ-treated U266 cells relative to untreated control cells (p < 0.05). Orange represents hypomethylation and green represents hypermethyla- tion (C) View of changes in the level of methylation in individual chromosomes. Orange repre- sents hypomethylation and green represents hypermethylation (p < 0.05). (D) Classification of differentially methylated sites in the genome according to their location relative to the CpG is- lands (p < 0.05). (E) Classification of differentially methylated sites in the genome according to their location relative to the transcription start site (TSS) (p < 0.05). (D—treated with vitamin 25(OH)D3; BTZ—treated with bortezomib; DK—treated simultaneously with vitamin 25(OH)D3 and K2MK7; BTZ_DK—treated simultaneously with bortezomib, vitamin 25(OH)D3, and K2MK7; Control—control group; 3—third incubation).

Article Snippet: The human multiple myeloma cell line U266 (ATCC, Manassas, VA, USA) was used in this study.

Techniques: Methylation, Control, Incubation

Journal: Nutrients

Article Title: Vitamin D and K Supplementation Is Associated with Changes in the Methylation Profile of U266-Multiple Myeloma Cells, Influencing the Proliferative Potential and Resistance to Bortezomib.

doi: 10.3390/nu16010142

Figure Lengend Snippet: Figure 3. GSEA shows biological processes whose genes showed a change in methylation levels in U266 cells treated three times with BTZ compared to control cells. Red indicates hypomethylation and green indicates hypermethylation. NES—normalized enrichment score.

Article Snippet: The human multiple myeloma cell line U266 (ATCC, Manassas, VA, USA) was used in this study.

Techniques: Methylation, Control

Journal: Nutrients

Article Title: Vitamin D and K Supplementation Is Associated with Changes in the Methylation Profile of U266-Multiple Myeloma Cells, Influencing the Proliferative Potential and Resistance to Bortezomib.

doi: 10.3390/nu16010142

Figure Lengend Snippet: Figure 4. Methylation profile after three VD treatments of U266 myeloma cells. (A,B) Charts show differences in methylation levels in U266 cells treated with VD relative to untreated control cells (p < 0.05). Orange represents hypomethylation and green represents hypermethylation (C) View of changes in the level of methylation in individual chromosomes. Orange represents hypomethylation and green represents hypermethylation (p < 0.05). (D) Classification of differentially methylated sites in the genome according to their location relative to the CpG islands (p < 0.05). (E) Classification of differentially methylated sites in the genome according to their location relative to the transcription start site (TSS) (p < 0.05). (D—treated with vitamin 25(OH)D3; BTZ—treated with bortezomib; DK—treated simultaneously with vitamin 25(OH)D3 and K2MK7; BTZ_DK—treated simultaneously with bortezomib, vitamin 25(OH)D3, and K2MK7; Control—control group; 3—third incubation).

Article Snippet: The human multiple myeloma cell line U266 (ATCC, Manassas, VA, USA) was used in this study.

Techniques: Methylation, Control, Incubation

Journal: Nutrients

Article Title: Vitamin D and K Supplementation Is Associated with Changes in the Methylation Profile of U266-Multiple Myeloma Cells, Influencing the Proliferative Potential and Resistance to Bortezomib.

doi: 10.3390/nu16010142

Figure Lengend Snippet: Figure 6. GSEA shows biological processes whose genes showed a change in methylation levels in U266 cells treated three times with VD compared to control cells. Red indicates hypomethylation and green indicates hypermethylation. NES—normalized enrichment score.

Article Snippet: The human multiple myeloma cell line U266 (ATCC, Manassas, VA, USA) was used in this study.

Techniques: Methylation, Control

Journal: Nutrients

Article Title: Vitamin D and K Supplementation Is Associated with Changes in the Methylation Profile of U266-Multiple Myeloma Cells, Influencing the Proliferative Potential and Resistance to Bortezomib.

doi: 10.3390/nu16010142

Figure Lengend Snippet: Figure 7. Methylation profile after three VD and VK treatments of U266 myeloma cells. (A,B) Charts show differences in methylation levels in U266 cells treated with VD and VK compared to un- treated control cells (p < 0.05). Orange represents hypomethylation and green represents hyper- methylation (C) View of changes in the level of methylation in individual chromosomes. Orange represents hypomethylation and green represents hypermethylation (p < 0.05). (D) Classification of differentially methylated sites in the genome according to their location relative to the CpG islands (p < 0.05). (E) Classification of differentially methylated sites in the genome according to their location relative to the transcription start site (TSS) (p < 0.05). (D—treated with vitamin 25(OH)D3; BTZ—treated with bortezomib; DK—treated simultaneously with vitamin 25(OH)D3 and K2MK7; BTZ_DK—treated simultaneously with bortezomib, vitamin 25(OH)D3, and K2MK7; Control—control group; 3—third incubation).

Article Snippet: The human multiple myeloma cell line U266 (ATCC, Manassas, VA, USA) was used in this study.

Techniques: Methylation, Control, Incubation

Journal: Nutrients

Article Title: Vitamin D and K Supplementation Is Associated with Changes in the Methylation Profile of U266-Multiple Myeloma Cells, Influencing the Proliferative Potential and Resistance to Bortezomib.

doi: 10.3390/nu16010142

Figure Lengend Snippet: Figure 9. GSEA shows the biological processes whose genes showed a change in methylation levels in U266 cells treated three times with VD and VK compared to control cells. Red indicates hypomethylation and green indicates hypermethylation. NES—normalized enrichment score.

Article Snippet: The human multiple myeloma cell line U266 (ATCC, Manassas, VA, USA) was used in this study.

Techniques: Methylation, Control

Journal: Nutrients

Article Title: Vitamin D and K Supplementation Is Associated with Changes in the Methylation Profile of U266-Multiple Myeloma Cells, Influencing the Proliferative Potential and Resistance to Bortezomib.

doi: 10.3390/nu16010142

Figure Lengend Snippet: Figure 10. Methylation profile after three subsequent BTZ, VD, and VK treatments of U266 myeloma cells. (A,B) Charts show differences in methylation levels in U266 cells treated with BTZ, VD, and VK relative to cells treated with BTZ alone (p < 0.05). Orange represents hypomethylation and green represents hypermethylation (C) View of changes in the level of methylation in individual chromosomes. Orange represents hypomethylation and green represents hypermethylation (p < 0.05). (D) Classification of differentially methylated sites in the genome according to their location relative to the CpG islands (p < 0.05). (E) Classification of differentially methylated sites in the genome according to their location relative to the transcription start site (TSS) (p < 0.05). (D—treated with vitamin 25(OH)D3; BTZ—treated with bortezomib; DK—treated simultaneously with vitamin 25(OH)D3 and K2MK7; BTZ_DK—treated simultaneously with bortezomib, vitamin 25(OH)D3, and K2MK7; Control—control group; 3—third incubation).

Article Snippet: The human multiple myeloma cell line U266 (ATCC, Manassas, VA, USA) was used in this study.

Techniques: Methylation, Control, Incubation

Journal: Nutrients

Article Title: Vitamin D and K Supplementation Is Associated with Changes in the Methylation Profile of U266-Multiple Myeloma Cells, Influencing the Proliferative Potential and Resistance to Bortezomib.

doi: 10.3390/nu16010142

Figure Lengend Snippet: Figure 12. (A) GSEA shows biological processes whose genes showed a change in methylation levels in U266 cells treated three times with BTZ, VD, and VK compared to cells treated three times with BTZ alone. Red indicates hypomethylation and green indicates hypermethylation. NES—normalized enrichment score. (B) number of observed methylation changes. Orange indicates hypomethylation, green indicates hypermethylation.

Article Snippet: The human multiple myeloma cell line U266 (ATCC, Manassas, VA, USA) was used in this study.

Techniques: Methylation